Cargando…

External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma

SIMPLE SUMMARY: Malignant pleural mesothelioma (MPM) is an incurable asbestos-related thoracic cancer for which early-stage diagnosis remains a major challenge. Volatile organic compounds (VOCs), which are metabolites present in exhaled breath, have proven to be promising non-invasive biomarkers for...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssens, Eline, Schillebeeckx, Eline, Zwijsen, Kathleen, Raskin, Jo, Van Cleemput, Joris, Surmont, Veerle F., Nackaerts, Kristiaan, Marcq, Elly, van Meerbeeck, Jan P., Lamote, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264774/
https://www.ncbi.nlm.nih.gov/pubmed/35804954
http://dx.doi.org/10.3390/cancers14133182
_version_ 1784743037125001216
author Janssens, Eline
Schillebeeckx, Eline
Zwijsen, Kathleen
Raskin, Jo
Van Cleemput, Joris
Surmont, Veerle F.
Nackaerts, Kristiaan
Marcq, Elly
van Meerbeeck, Jan P.
Lamote, Kevin
author_facet Janssens, Eline
Schillebeeckx, Eline
Zwijsen, Kathleen
Raskin, Jo
Van Cleemput, Joris
Surmont, Veerle F.
Nackaerts, Kristiaan
Marcq, Elly
van Meerbeeck, Jan P.
Lamote, Kevin
author_sort Janssens, Eline
collection PubMed
description SIMPLE SUMMARY: Malignant pleural mesothelioma (MPM) is an incurable asbestos-related thoracic cancer for which early-stage diagnosis remains a major challenge. Volatile organic compounds (VOCs), which are metabolites present in exhaled breath, have proven to be promising non-invasive biomarkers for MPM. However, without the necessary validation in an independent group of individuals, clinical implementation is hampered. Therefore, we performed external validation of a VOC-based prediction model for MPM, which initially revealed a poor performance and thus poor generalisability of the model. However, subsequent updating of the model improved its performance in the validation cohort, resulting in a more generalisable model with a screening potential, which could significantly impact MPM management. ABSTRACT: During the past decade, volatile organic compounds (VOCs) in exhaled breath have emerged as promising biomarkers for malignant pleural mesothelioma (MPM). However, as these biomarkers lack external validation, no breath test for MPM has been implemented in clinical practice. To address this issue, we performed the first external validation of a VOC-based prediction model for MPM. The external validation cohort was prospectively recruited, consisting of 47 MPM patients and 76 asbestos-exposed (AEx) controls. The predictive performance of the previously developed model was assessed by determining the degree of agreement between the predicted and actual outcome of the participants (patient/control). Additionally, to optimise the performance, the model was updated by refitting it to the validation cohort. External validation revealed a poor performance of the original model as the accuracy was estimated at only 41%, indicating poor generalisability. However, subsequent updating of the model improved the differentiation between MPM patients and AEx controls significantly (73% accuracy, 92% sensitivity, and 92% negative predictive value), substantiating the validity of the original predictors. This updated model will be more generalisable to the target population and exhibits key characteristics of a potential screening test for MPM, which could significantly impact MPM management.
format Online
Article
Text
id pubmed-9264774
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92647742022-07-09 External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma Janssens, Eline Schillebeeckx, Eline Zwijsen, Kathleen Raskin, Jo Van Cleemput, Joris Surmont, Veerle F. Nackaerts, Kristiaan Marcq, Elly van Meerbeeck, Jan P. Lamote, Kevin Cancers (Basel) Article SIMPLE SUMMARY: Malignant pleural mesothelioma (MPM) is an incurable asbestos-related thoracic cancer for which early-stage diagnosis remains a major challenge. Volatile organic compounds (VOCs), which are metabolites present in exhaled breath, have proven to be promising non-invasive biomarkers for MPM. However, without the necessary validation in an independent group of individuals, clinical implementation is hampered. Therefore, we performed external validation of a VOC-based prediction model for MPM, which initially revealed a poor performance and thus poor generalisability of the model. However, subsequent updating of the model improved its performance in the validation cohort, resulting in a more generalisable model with a screening potential, which could significantly impact MPM management. ABSTRACT: During the past decade, volatile organic compounds (VOCs) in exhaled breath have emerged as promising biomarkers for malignant pleural mesothelioma (MPM). However, as these biomarkers lack external validation, no breath test for MPM has been implemented in clinical practice. To address this issue, we performed the first external validation of a VOC-based prediction model for MPM. The external validation cohort was prospectively recruited, consisting of 47 MPM patients and 76 asbestos-exposed (AEx) controls. The predictive performance of the previously developed model was assessed by determining the degree of agreement between the predicted and actual outcome of the participants (patient/control). Additionally, to optimise the performance, the model was updated by refitting it to the validation cohort. External validation revealed a poor performance of the original model as the accuracy was estimated at only 41%, indicating poor generalisability. However, subsequent updating of the model improved the differentiation between MPM patients and AEx controls significantly (73% accuracy, 92% sensitivity, and 92% negative predictive value), substantiating the validity of the original predictors. This updated model will be more generalisable to the target population and exhibits key characteristics of a potential screening test for MPM, which could significantly impact MPM management. MDPI 2022-06-29 /pmc/articles/PMC9264774/ /pubmed/35804954 http://dx.doi.org/10.3390/cancers14133182 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Janssens, Eline
Schillebeeckx, Eline
Zwijsen, Kathleen
Raskin, Jo
Van Cleemput, Joris
Surmont, Veerle F.
Nackaerts, Kristiaan
Marcq, Elly
van Meerbeeck, Jan P.
Lamote, Kevin
External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma
title External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma
title_full External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma
title_fullStr External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma
title_full_unstemmed External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma
title_short External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma
title_sort external validation of a breath-based prediction model for malignant pleural mesothelioma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264774/
https://www.ncbi.nlm.nih.gov/pubmed/35804954
http://dx.doi.org/10.3390/cancers14133182
work_keys_str_mv AT janssenseline externalvalidationofabreathbasedpredictionmodelformalignantpleuralmesothelioma
AT schillebeeckxeline externalvalidationofabreathbasedpredictionmodelformalignantpleuralmesothelioma
AT zwijsenkathleen externalvalidationofabreathbasedpredictionmodelformalignantpleuralmesothelioma
AT raskinjo externalvalidationofabreathbasedpredictionmodelformalignantpleuralmesothelioma
AT vancleemputjoris externalvalidationofabreathbasedpredictionmodelformalignantpleuralmesothelioma
AT surmontveerlef externalvalidationofabreathbasedpredictionmodelformalignantpleuralmesothelioma
AT nackaertskristiaan externalvalidationofabreathbasedpredictionmodelformalignantpleuralmesothelioma
AT marcqelly externalvalidationofabreathbasedpredictionmodelformalignantpleuralmesothelioma
AT vanmeerbeeckjanp externalvalidationofabreathbasedpredictionmodelformalignantpleuralmesothelioma
AT lamotekevin externalvalidationofabreathbasedpredictionmodelformalignantpleuralmesothelioma